Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor
Portfolio Pulse from
Scilex Bio, a joint venture of Scilex Holding Company, reports positive Phase 1 trial results for KDS2010, a new MAO-B inhibitor, and is enrolling for a Phase 2 obesity trial with a U.S. cohort to be added in 2025.
December 11, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex Holding Company, through its joint venture Scilex Bio, reports positive Phase 1 results for KDS2010 and is progressing with a Phase 2 obesity trial. This could enhance Scilex's product pipeline and market position.
The positive Phase 1 results for KDS2010 and the ongoing Phase 2 trial for obesity suggest potential future product offerings, which could positively impact Scilex's market position and stock price. The addition of a U.S. cohort in 2025 indicates a strategic expansion in a key market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90